publication date: Sep. 11, 2015
Gianni Bonadonna, 81, Pioneering Cancer Researcher
Gianni Bonadonna, 81, a pioneering cancer researcher whose work focused on Hodgkin’s lymphoma and breast cancer, died Sept. 7.
His death was announced by the Istituto Nazionale Tumori of Milan.
Bonadonna research included the initial studies on the clinical efficacy of adriamycin (doxorubicin), epirubicin and bleomycin; a number of seminal trials on adjuvant and primary chemotherapy for high-risk breast cancer; as well as a combined modality for the treatment of Hodgkin’s disease—in 1972, he designed a new combination of drugs known as ABVD: adriamycin, bleomycin, vinblastine and dacarbazine.
In 1973, he designed and conducted the first clinical trial to evaluate the efficacy of the combination CMF (cyclophosphamide, methotrexate and fluorouracil) as postoperative adjuvant treatment for breast carcinomas at a high risk of relapse.
Bonadonna was born in Milan in 1934. He received his medical degree from the University of Milano in 1959. He did his fellowship at Memorial Sloan Kettering Cancer Center from 1961 to 1964.
He then joined the Istituto Nazionale Tumori, where he became director of the Division of Medical Oncology in 1976. In 1991, he was appointed head of the Department of Cancer Medicine in the same institution and associate professor at the School of Hematology of the University in Milan. Since 1999, he has been founder and president of the Fondazione Michelangelo.
As a visiting professor in several universities all over the world, Bonadonna … Continue reading 41-33 Gianni Bonadonna, 81, Pioneering Cancer Researcher
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.